Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s274, 2023. DOI: 10.25251/skin.7.supp.274. Disponível em: https://skin.dermsquared.com/skin/article/view/2385. Acesso em: 19 apr. 2026.